Infinite Epigenetics agreed to acquire Tally Health, a move aimed at building a diagnostics-to-intervention platform spanning epigenetic testing, adult DNA methylation datasets, and personalized healthspan programs. The combined offering is designed to connect biomarker readouts to follow-on therapeutic or lifestyle recommendations. The acquisition underscores how epigenetics companies are consolidating datasets and product capabilities to differentiate beyond standalone lab tests. For industry observers, the key question will be how quickly the merged platform can translate methylation signals into validated intervention pathways. The deal also reflects continuing investor and corporate interest in multi-layer diagnostic businesses that can scale across consumer and clinical markets.